<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02697838</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-G323</org_study_id>
    <nct_id>NCT02697838</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer</brief_title>
  <official_title>Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single arm study: Apatinib plus paclitaxel as the reverses treatment in advanced gastric
      cancer which paclitaxel-resistant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial investigated the efficacy and safety of apatinib plus paclitaxel, as a treatment
      option for patients with advanced gastric cancer which paclitaxel-resistant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease control rate(DCR)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Malignant Neoplasm of Stomach Stage II</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib Mesylate Tablets (850 mg qd p.o.) and Paclitaxel (80mg/m2 i.v. d1, d8, d15, q28d)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib (850 mg qd p.o.) plus paclitaxel (80mg/m2, i.v. d1,d8, d15, q28d)until disease progression or intolerable toxicity</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>ATAN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: more than 18 years old;

          2. Histologically confirmed advanced or metastatic adenocarcinoma of gastric cancer(AGC)
             , including adenocarcinoma of the gastroesophageal junction;

          3. At least one measurable and evaluable disease based on response evaluation criteria in
             solid tumors (RECIST v1.1);

          4. The patient with Prior Paclitaxel-Resistant;

          5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2;

          6. An expected survival of ≥ 3 months;

          7. Duration from the last therapy is more than 6 weeks for nitroso or mitomycin, More
             than 4 weeks for other cytotoxic agents, operation or radiotherapy;

          8. Major organ function has to meet the following criteria; (1) For results of blood
             routine test:

               1. Hemoglobin (HB) ≥ 80g / L,

               2. ANC ≥ 1.5 × 109 / L,

               3. PLT ≥ 75 × 109 / L, (2) For results of biochemical tests:

               1. BLT ≤ 1.25 times the upper limit of normal (ULN),

               2. ALT and AST ≤ 2.5 × ULN, liver metastases, if any, the ALT and AST≤ 5 × ULN,

               3. Serum Cr≤1ULN, Endogenous creatinine clearance rate ＞50ml/min;

          9. Pregnancy test (serum or urine) has to be performed for woman of childbearing age
             within 7 days before enrolment and the test result must be negative. They shall take
             appropriate methods for contraception during the study until the 8th week post the
             last administration of study drug. For men, (previous surgical sterilization
             accepted), shall agree to take appropriate methods of contraception during the study
             until the 8th week post the last administration of study drug;

         10. Patient has to voluntarily join the study and sign the Informed Consent Form for the
             study.

        Exclusion Criteria:

          1. History of other malignancies except cured basal cell carcinoma of skin and carcinoma
             insitu of uterine cervix;

          2. Confirmed that apatinib and/or its accessories allergy;

          3. Subjects with poor-controlled arterial hypertension (systolic blood pressure&gt; 140 mmHg
             and diastolic blood pressure &gt; 90 mm Hg) despite standard medical management;

          4. Serious cardiovascular disease: Ⅱ-level myocardial ischemia or myocardial infarction,
             arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms);
             III ~ IV level cardiac function insufficiency, or echocardiography showed that left
             ventricular ejection fraction (LVEF &lt; 50%);

          5. Patients with positive urinary protein (urine protein detection of 2 or more, or 24
             hour urine protein &gt;1.0g);

          6. Factors that could have an effect on oral medication (such as inability to swallow,
             chronic diarrhea and intestinal obstruction);

          7. Subjects with high gastrointestinal bleeding risk, including the following conditions:
             local active ulcer lesions with positive fecal occult blood test (++); history of
             black stool, or vomiting blood in the past 2 months;unresected primary lesion in
             stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with
             massive alimentary tract bleeding risk judged by PIs based on gastric endoscopy
             result;

          8. Abnormal Coagulation (INR&gt;1.5、APTT&gt;1.5 UNL), with tendency of bleed;

          9. With psychotropic drug abuse history and can't get rid or with mental disorder
             patients;

         10. Less than 4 weeks from the last clinical trial;

         11. According to the researcher's judgment, with other serious diseases which harm to
             patient safety or affect patients complete the study;

         12. Evidence of central nervous system(CNS) metastasis;

         13. Pregnant or lactating women;

         14. Other conditions regimented at investigators' discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rongbo Lin, MD</last_name>
    <phone>086+13705919382</phone>
    <email>rongbo_lin@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rongbo Lin</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rongbo Lin, MD</last_name>
      <phone>86+13705919382</phone>
      <email>rongbo_lin@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

